Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis

Inflammatory Bowel Diseases

Volumn 17, Issue 1, 2011, Pages 289-297

  Uronis, Joshua M ^a   Arthur, Janelle C ^a   Keku, Temitope ^a   Fodor, Anthony ^b   Carroll, Ian M ^a   Cruz, Myrella L ^c   Appleyard, Caroline B ^c   Jobin, Christian ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Charlotte   (United States)

^c PONCE SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

inflammatory bowel diseases; microbiota; probiotic; T RFLP; VSL 3

Indexed keywords

BACTERIAL RNA; PROBIOTIC AGENT; RNA 16S; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; CHRONIC COLITIS; COLITIS; CONTROLLED STUDY; HOMEOSTASIS; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS PLANTARUM; MALE; MICROBIAL COMMUNITY; MICROBIAL DIVERSITY; NONHUMAN; PRIORITY JOURNAL; RAT; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RNA GENE; STREPTOCOCCUS SALIVARIUS; TERMINAL RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ANIMALS; COLITIS; MALE; METAGENOME; PROBIOTICS; RATS; RATS, SPRAGUE-DAWLEY; TRINITROBENZENESULFONIC ACID;

EID: 78650107219     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21366     Document Type: Article

References (37)

1. Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007; 104: 13780-13785.
2. Neish AS,. Microbes in gastrointestinal health and disease. Gastroenterology. 2009; 136: 65-80.
3. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010; 464: 59-65.
4. Hooper LV, Stappenbeck TS, Hong CV, et al. Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat Immunol. 2003; 4: 269-273.
5. Stappenbeck TS, Hooper LV, Gordon JI,. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci U S A. 2002; 99: 15451-15455.
6. Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature. 2007; 449: 804-810.
7. Xu J, Gordon JI,. Inaugural article: honor thy symbionts. Proc Natl Acad Sci U S A. 2003; 100: 10452-10459.
8. Xavier RJ, Podolsky DK,. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448: 427-434.
9. Strober W, Fuss I, Mannon P,. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007; 117: 514-521.
10. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001; 121: 580-591.
11. Madsen KL, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology. 1999; 116: 1107-1114.
12. Pagnini C, Saeed R, Bamias G, et al. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc Natl Acad Sci U S A. 2010; 107: 454-459.
13. Ahn C, Stiles ME,. Antibacterial activity of lactic acid bacteria isolated from vacuum-packaged meats. J Appl Bacteriol. 1990; 69: 302-310.
14. Madsen K,. Probiotics and the immune response. J Clin Gastroenterol. 2006; 40: 232-234.
15. Marteau PR, de Vrese M, Cellier CJ, et al. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr. 2001; 73: 430S-436S.
16. Pessi T, Sutas Y, Marttinen A, et al. Probiotics reinforce mucosal degradation of antigens in rats: implications for therapeutic use of probiotics. J Nutr. 1998; 128: 2313-2318.
17. Pessi T, Sutas Y, Saxelin M, et al. Antiproliferative effects of homogenates derived from five strains of candidate probiotic bacteria. Appl Environ Microbiol. 1999; 65: 4725-4728.
18. Wang X, O'Gorman MR, Bu HF, et al. Probiotic preparation VSL#3 alters the distribution and phenotypes of dendritic cells within the intestinal mucosa in C57BL/10J mice. J Nutr. 2009; 139: 1595-1602.
19. Lin MY, Chang FJ,. Antioxidative effect of intestinal bacteria Bifidobacterium longum ATCC 15708 and Lactobacillus acidophilus ATCC 4356. Dig Dis Sci. 2000; 45: 1617-1622.
20. Isolauri E, Majamaa H, Arvola T, et al. Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology. 1993; 105: 1643-1650. (Pubitemid 24002779)
21. Okamoto T, Sasaki M, Tsujikawa T, et al. Preventive efficacy of butyrate enemas and oral administration of Clostridium butyricum M588 in dextran sodium sulfate-induced colitis in rats. J Gastroenterol. 2000; 35: 341-346.
22. Corr SC, Li Y, Riedel CU, et al. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci U S A. 2007; 104: 7617-7621.
23. Appleyard CB, Wallace JL,. Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am J Physiol. 1995; 269: G119-G125.
24. Santiago C, Pagan B, Isidro AA, et al. Prolonged chronic inflammation progresses to dysplasia in a novel rat model of colitis-associated colon cancer. Cancer Res. 2007; 67: 10766-10773.
25. Furet JP, Quenee P, Tailliez P,. Molecular quantification of lactic acid bacteria in fermented milk products using real-time quantitative PCR. Int J Food Microbiol. 2004; 97: 197-207.
26. Yan F, Polk DB,. Probiotics: progress toward novel therapies for intestinal diseases. Curr Opin Gastroenterol. 2010; 26: 95-101.
27. Costello EK, Lauber CL, Hamady M, et al. Bacterial community variation in human body habitats across space and time. Science. 2009; 326: 1694-1697.
28. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005; 308: 1635-1638.
29. Gionchetti P, Rizzello F, Morselli C, et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum. 2007; 50: 2075-2082; discussion 2082-2074.
30. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009; 7: 1202-1209, 1209 e1201.
31. Gorbach SL, Barza M, Giuliano M, et al. Colonization resistance of the human intestinal microflora: testing the hypothesis in normal volunteers. Eur J Clin Microbiol Infect Dis. 1988; 7: 98-102.
32. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006; 55: 205-211.
33. Prisciandaro L, Geier M, Butler R, et al. Probiotics and their derivatives as treatments for inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15: 1906-1914.
34. Sokol H, Lay C, Seksik P, et al. Analysis of bacterial bowel communities of IBD patients: what has it revealed? Inflamm Bowel Dis. 2008; 14: 858-867.
35. Heuvelin E, Lebreton C, Grangette C, et al. Mechanisms involved in alleviation of intestinal inflammation by bifidobacterium breve soluble factors. PLoS One. 2009; 4: e5184.
36. Seth A, Yan F, Polk DB, et al. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism. Am J Physiol Gastrointest Liver Physiol. 2008; 294: G1060-1069.
37. Grangette C, Nutten S, Palumbo E, et al. Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc Natl Acad Sci USA. 2005; 102: 10321-10326.